Passive immunization for the public health control of communicable diseases : Current status in four high-income countries and where to next

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1885-1893

  Young, Megan K ^a   Cripps, Allan W ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Communicable disease control; Evidence based practice; Immunoglobulins; Passive immunization; Practice guidelines

Indexed keywords

HEPATITIS A VACCINE; IMMUNOGLOBULIN;

ANTIBODY TITER; COMMUNICABLE DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PRACTICE; HEPATITIS A; HUMAN; INFECTION PREVENTION; INFECTION RESISTANCE; PASSIVE IMMUNIZATION; PUBLIC HEALTH; REVIEW;

COMMUNICABLE DISEASE CONTROL; EVIDENCE BASED PRACTICE; IMMUNOGLOBULINS; PASSIVE IMMUNIZATION; PRACTICE GUIDELINES;

AUSTRALIA; DEVELOPED COUNTRIES; GREAT BRITAIN; HEPATITIS A; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MEASLES; NEW ZEALAND; RUBELLA; UNITED STATES;

EID: 84884627668     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25311     Document Type: Review

References (106)

1. McDonagh TJ. Passive immunization with gamma globulin. J Occup Med 1966; 8:567-72; PMID:4163204
2. Gonik B. Passive immunization: the forgotten arm of immunologically based strategies for disease containment. Am J Obstet Gynecol 2011; 205:e1-6; PMID:21893309; http://dx.doi.org/10.1016/j.ajog.2011.06.076
3. Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Arch Virol 2007; 152:1047-59; PMID:17516034; http://dx.doi.org/10. 1007/s00705-006-0923-8
4. Birdsall H. Antibodies. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett's Priniciples and Practice of Infectious Diseases. Philadelphia: Chruchill Livengstone, 2009.
5. Law M, Hangartner L. Antibodies against viruses: passive and active immunization. Curr Opin Immunol 2008; 20:486-92; PMID:18577455; http://dx.doi.org/10.1016/j.coi.2008.06.005
6. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2:706-13; PMID:12209139; http://dx.doi.org/10.1038/nri891
7. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28:737-64, viii; PMID:18940572; http://dx.doi.org/10.1016/j.iac. 2008.06.004
8. Zingher A, Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187. Rev Med Virol 2005; 15:407-18, discussion 418-21; PMID:16211552; http://dx.doi.org/10.1002/rmv.480
9. MIMS online. Normal Immunoglobulin-VF: Medica UBM. 2011 [cited 2012 18 Sept] Available from: https://www.mimsonline.com.au.
10. Annex WHO. 2: Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. In: WHO, ed. WHO Technical Report Series, 1994.
11. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21:101-17; PMID:17397761; http://dx.doi.org/10.1016/j.tmrv.2006.11.001
12. CDNA. Measles: National guidelines for public health units. Canberra: Commonwealth Department of Health and Ageing, 2009.
13. CDNA. Hepatitis A: National guidelines for public health units. Canberra: Commonwealth Government, 2009.
14. Ramsay M, Manikkavasagan G, Brown K, Craig L. Post exposure prophylaxis for measles: revised guidance May 2009. UK: Health Protection Agency, 2009.
15. Thomas L, and the Hepatitis A Guidelines Group. Guidance for the Prevention and Control of Hepatitis A Infection. London: Health Protection Agency, 2009.
16. Ministry of Health. Immunization Handbook 2011. Wellington: Ministry of Health, 2011.
17. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57; PMID:9639369
18. Advisory Committee on Immunization Practices (ACIP). Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-7):1-23
19. Victorian Department of Health. Infectious diseases epidemiology and surveillance: Rubella (German measles). Melbourne: Department of Health, Victoria, Australia, 2007.
20. Health Q. Rubella: Queensland Health Guidelines for Public Health Units. Brisbane: Queensland Government, 2010.
21. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep 2001; 50(RR-12):1-23; PMID:11475328
22. Immunization Department. Rubella. Immunoglobulin Handbook. UK: Health Protection Agency, 2009.
23. Immunization Department. Measles. Immunoglobulin Handbook. UK: Health Protection Agency, 2009.
24. Immunization Department. Hepatitis A. Immunoglobulin Handbook. UK: Health Protection Agency, 2009.
25. UK Department of Health. Chapter 17: Hepatitis A - updated 9 February 2011. Immunization against infectious disease - "The Green Book" - 2006 updated edition. UK: Department of Health, UK, 2011.
26. UK Department of Health. Chapter 28: Rubella - file replaced 14 December 2010. Immunization against infectious disease - "The Green Book" - 2006 updated edition. UK: Department of Health, UK, 2010.
27. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1080-4; PMID:17947967
28. Best V, Roberts F. Measles - Infection Control Definitions & Guidelines. In: Gavin R, ed. Starship Children's Health Clinical Guideline. Auckland, New Zealand: Auckland District Health Board, 2011.
29. New South Wales Health. Control Guideline: Rubella. Sydney: NSW government, 2004.
30. Australian Technical Advisory Group on Immunization. The Australian Immunization Handbook 10th edition. Canberra: Commonwealth of Australia, 2013.
31. The World Bank. Data: GDP per capita (current US$). The World Bank Group, 2012 [cited 2012, 23 July]; Available from: http://data.worldbank.org/ indicator/NY.GDP.PCAP.CD?order=wbapi-data-value-2010+wbapi-data-value&sort= desc.
32. World Health Organisation. The Global Burden of Disease 2004 Update. Geneva: World Health Organisation, 2008.
33. OECD. OECD Health Data 2012 - Frequently Requested Data. 2012 [cited 2012 23 July]; Available from: http://www.oecd.org/document/16/0,3746, en-2649-37407-2085200-1-1-1-37407,00.html.
34. Central Intelligence Agency. The World Factbook: Ethnic Groups. 2012 [updated weekly; cited 2012 23 July]; Available from: https://www.cia.gov/ library/publications/the-world-factbook/fields/2075.html.
35. World Health Organisation Department of Measurement and Health Information. Mortality and Burden of Disease Estimates for WHO Member States in 2004. WHO, 2009 [cited 2012 23 July]; Available from: http://www.who.int/ healthinfo/global-burden-disease/estimates-country/en/index.html.
36. NCIRS. Vaccine preventable disease in Australia, 2005 to 2007. Communicable Diseases Intelligence. Canberra: Australian Government Department of Health and Ageing, 2010.
37. World Health Organisation. WHO Vaccine Preventable Diseases Monitoring System 2011 Global Summary. World Health Organisation, 2012 [updated 3 October 2011 (data as of 27 Sept 2011); cited 2012 Feb 21]; Available from: http://apps.who.int/immunization-monitoring/en/globalsummary/ countryprofileselect. cfm.
38. Health Protection Agency. Vaccination Schedule: Routine childhood immunization schedule. London: Health Protection Agency, 2011 [cited 2012 Jan 2]; Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/VaccineCoverageAndCOVER/VaccinationSchedule/.
39. Recommended immunization schedules for persons aged 0-18 years - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:1-4
40. Jacobsen K. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Geneva: Immunization, Vaccines and Biologicals, World Health Organization, 2009.
41. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28:6653-7; PMID:20723630; http://dx.doi.org/10.1016/j.vaccine.2010.08.037
42. Gidding HF, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007; 25:3574-80; PMID:17300858; http://dx.doi.org/10.1016/ j.vaccine.2007.01.090
43. Vyse AJ, Gay NJ, Hesketh LM, Pebody R, Morgan-Capner P, Miller E. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiol Infect 2006; 134:1303-12; PMID:16650326; http://dx.doi.org/ 10.1017/S0950268806006340
44. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007; 196:1459-64; PMID:18008224; http://dx.doi.org/10.1086/522866
45. Weir R, Jennings L, Young S, Brunton C, Murdoch D. National serosurvey of vaccine preventable diseases: report to the Ministry of Health. Wellington: Ministry of Health, 2009.
46. Gilbert GL, Escott RG, Gidding HF, Turnbull FM, Heath TC, McIntyre PB, et al. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol Infect 2001; 127:297-303; PMID:11693507; http://dx.doi.org/10.1017/S0950268801005830
47. Kelly H, Worth L, Karapanagiotidis T, Riddell M. Interruption of rubella virus transmission in Australia may require vaccination of adult males: evidence from a Victorian sero-survey. Commun Dis Intell Q Rep 2004; 28:69-73; PMID:15072157
48. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006; 43(Suppl 3):S146-50; PMID:16998774; http://dx.doi.org/10.1086/505947
49. Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, Olin P, Berbers G, Rebiere I, et al. The seroepidemiology of rubella in western Europe. Epidemiol Infect 2000; 125:347-57; PMID:11117958; http://dx.doi.org/10.1017/S0950268899004574
50. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21, vii; PMID:20123436; http://dx.doi.org/ 10.1016/j.cld.2009.11.009
51. UNAIDS. AIDSinfo Epidemiological Status. 2009 [cited 2012 18 Sept]; Available from: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/.
52. US Food and Drug Administration. Vaccines, Blood & Biologics: Blood and blood products. 2012 [cited 2012 18 Sept]; Available from: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/default.htm.
53. Bio Products Laboratory. Patient information leaflet: Subgam, Human normal immunoglobulin solution. Hertfordshire, UK 2009.
54. Sinden J. Datasheet: Normal Immunoglobulin-VF. Auckland: CSL New Zealand Limited, 2008.
55. CodeBlueNow! Comparison of Health Care Systems. Seattle: CodeBlueNow! 2008 [cited 2012 23 July]; Available from: http://conversations.psu.edu/docs/ calkins-comparison.pdf
56. World Health Organisation. WHOSIS: WHO Statistical Information System. 2008 [cited 2012 23 July]; Available from: http://apps.who.int/whosis/data/ Search.jsp.
57. Harper WS, Tayback ML, Williams H. The efficacy of gamma globulin in the prevention of measles. Md State Med J 1957; 6:67-9; PMID:13407194
58. Sheppeard V, Forssman B, Ferson MJ, Moreira C, Campbell-Lloyd S, Dwyer DE, et al. The effectiveness of prophylaxis for measles contacts in NSW. New South Wales Public. Health Bull (Edinb) 2009; 20:81-5; http://dx.doi.org/10. 1071/NB08014
59. Schiff GM. Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. Am J Dis Child 1969; 118:322-7; PMID:4183352
60. Waagner D. Childhood exanthems. In: Kaplan S, ed. Current Therapy in Pediatric Infectious Diseases. Saint Louis: Mosby-Year Book, Inc., 1993:274-8.
61. Petersen EE, Neumann-Haefelin D, Heussler M. Rubella in pregnancy: experimental studies on the value of gamma-globulin after rubella wild virus infection (author's transl). Dtsch Med Wochenschr 1978; 103:1695-700; PMID:81125; http://dx.doi.org/10.1055/s-0028-1129325
62. Neumann-Haefelin D, Neumann-Haefelin Ch, Petersen EE, Luthardt Th, Hass R. Passive immunization against rubella: studies on the effectiveness of rubella-immunoglobulin after intranasal infection with rubella vaccination virus. Dtsch Med Wochenschr 1975; 100:177-81; PMID:1112230; http://dx.doi.org/ 10.1055/s-0028-1106191
63. Prophylaxis in rubella. Br Med J 1967; 4:183-4; PMID:4167915; http://dx.doi.org/10.1136/bmj.4.5573.183
64. Prevention of rubella malformations. Br Med J 1968; 3:199-200; PMID:4173959; http://dx.doi.org/10.1136/bmj.3.5612.199
65. Doege TC, Kim KS. Studies of rubella and its prevention with immune globulin. JAMA 1967; 200:584-90; PMID:4164596; http://dx.doi.org/10.1001/jama. 1967.03120200062008
66. Green R, Balsamo M, Giles J, Krugman S, Mirick G. Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Virusforschung 1965; 16:513-6; http://dx.doi.org/10.1007/BF01253868
67. Bass M, Davidson HB, Foote F, Muckenfuss R. The efficacy of gamma globulin in the prevention of German measles. NY Med 1949; 5:21-3; PMID:15394138
68. Liu JP, Nikolova D, Fei Y. Immunoglobulins for preventing hepatitis A. Cochrane Database Syst Rev 2009; CD004181; PMID:19370595
69. Mosley JW, Reisler DM, Brachott D, Roth D, Weiser J. Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis. Am J Epidemiol 1968; 87:539-50; PMID:4297614
70. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357:1685-94; PMID:17947390; http://dx.doi.org/10.1056/ NEJMoa070546
71. Bianco E, De Masi S, Mele A, Jefferson T. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Dig Liver Dis 2004; 36:834-42; PMID:15646432; http://dx.doi.org/10.1016/ j.dld.2004.07.014
72. Pollock T, Reid D. Assessment of British gammaglobulin in preventing infectious hepatitis. A report to the director of the Public Health Laboratory Service. Br Med J 1968; 3:451-4; PMID:4174401; http://dx.doi.org/10.1136/bmj.3. 5616.451
73. Dayan GH, Ortega-Sánchez IR, LeBaron CW, Quinlisk MP, Team IMR; Iowa Measles Response Team. The cost of containing one case of measles: the economic impact on the public health infrastructure-Iowa, 2004. Pediatrics 2005; 116:e1-4; PMID:15995008; http://dx.doi.org/10.1542/peds.2004-2512
74. Stuart R, Bradford J, Leszkiewicz P, Wilson J, Gillespie E. The costs of containing measles within a health care service. Healthc Infect 2010; 15:43-6; http://dx.doi.org/10.1071/HI10008
75. Rosenberg ML, Koplan JP, Pollard RA. The risk of acquiring hepatitis from sewage-contaminated water. Am J Epidemiol 1980; 112:17-22; PMID:6772022
76. Pavia AT, Nielsen L, Armington L, Thurman DJ, Tierney E, Nichols CR. A community-wide outbreak of hepatitis A in a religious community: impact of mass administration of immune globulin. Am J Epidemiol 1990; 131:1085-93; PMID:2343861
77. Gillis D, Yetiv N, Gdalevich M, Mimouni D, Ashkenazi I, Shpilberg O, et al. Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis. Vaccine 2000; 18:3005-10; PMID:10825603; http://dx.doi.org/10.1016/S0264-410X(00)00091-8
78. Egoz N. Cost-benefit of mass prophylaxis with immune serum globulin to control waterborne hepatitis A: a case study. Isr J Med Sci 1986; 22:277-82; PMID:3091532
79. American Red Cross. American Red Cross - About Us. 2012 [cited 2012 23 July]; Available from: http://www.redcrossblood.org/about-us.
80. America's Blood Centers. America's Blood Centers - About Us. 2012 [cited 2012 23 July]; Available from: http://www.americasblood.org/go.cfm?do=Page. View&pid=29.
81. NHS Blood and Transplant. Home page. 2012 [cited 2012 23 July]; Available from: http://www.nhsbt.nhs.uk/index.asp.
82. Australian Red Cross Blood Service. Blood collection and testing. 2012 [updated 2011, 23 Dec; cited 2012 23 July]; Available from: http://www. transfusion.com.au/blood-products/collection-testing.
83. New Zealand Blood Service. What we do. 2012 [cited 2012 23 July]; Available from: http://www.nzblood.co.nz/About-NZBS/What-we-do.
84. World Health Organisation. Blood Safety: GDBS Summary Report 2011. WHO, 2011.
85. McClelland D, ed. Handbook of Transfusion Medicine. London: The Stationery Office, 2007.
86. Flood P, Wills P, Lawler P, Ryan G, Rickard K. Review of Australia's Plasma Fractionation Arrangements. Canberra: Commonwealth of Australia, 2006. http://www.health.gov.au/plasmafractionationreview
87. Papania M, Beller J, Scott D. Measles post-exposure prophylaxis with immune globulin products. Atlanta, Georgia: Centres for Disease Control, 2012 [cited 2012 23 July]; Available from: http://www.cdc.gov/vaccines/recs/acip/ downloads/mtg-slides-jun12/03-MMR-Papania.pdf.
88. Poutasi K. Re: Review of Australia's Plasma Fractionation Arrangements. 2006.
89. National Blood Authority Australia. Recombinant and plasma supply contracts. 2012 [updated 2011, 6 June; cited 2012 23 July]; Available from: http://www.nba.gov.au/supply/recombinant.html.
90. European Pharmacopoeia. Strasbourg, France: European Department for the Quality of Medicines, Council of Europe, 2008.
91. Rabenau HF, Marianov B, Wicker S, Allwinn R. Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations. Med Microbiol Immunol 2007; 196:151-5; PMID:17308917; http://dx.doi.org/10.1007/s00430-007-0037-2
92. Endo A, Izumi H, Miyashita M, Taniguchi K, Okubo O, Harada K. Current efficacy of postexposure prophylaxis against measles with immunoglobulin. J Pediatr 2001; 138:926-8; PMID:11391343; http://dx.doi.org/10.1067/mpd.2001. 113710
93. US Food and Drug Administration. CFR - Code of Federal Regulations Title 21. 2011.
94. Dayan G, Rota J, Bellini W, Redd S. Chapter 7: Measles. In: Roush S, McIntyre L, Baldy L, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. Atlanta, USA: Centers for Disease Control and Prevention, 2008.
95. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book. Washington DC: Public Health Foundation, 2012.
96. Australian Technical Advisory Group on Immunization. The Australian Immunization handbook 9th edition. Canberra: Australian Government, 2008.
97. Health Protection Agency. Statutory Notification of Hepatitis A by Region, England and Wales, 1990-2009. HPA, 2011 2011 [updated 29 December 2011; cited 2012 21 Feb]; Available from: http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/1195733845348.
98. Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern Ireland - mid 2009. Office for National Statistics, 2010 [cited 2012 21 Feb]; Available from: http://www.ons.gov.uk/ons/ publications/re-reference-tables.html?edition=tcm%3A77-213645.
99. Advisory Committee on Immunization Practices. Resolution No. 06/07-1 Vaccines for children program: vaccines to prevent hepatitis A. Centers for Disease Control and Prevention, 2007 [updated Adopted and effective 27 Jun 2007; cited 2012 21 Feb]; Available from: http://www.cdc.gov/vaccines/programs/vfc/ downloads/resolutions/0607-1hepa.pdf.
100. Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med J Aust 2001; 174:338-41; PMID:11346106
101. Morris MC, Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. The changing epidemiological pattern of hepatitis A in England and Wales. Epidemiol Infect 2002; 128:457-63; PMID:12113490; http://dx.doi.org/10.1017/S095026880200701X
102. Klevens RM, Kruszon-Moran D, Wasley A, Gallagher K, McQuillan GM, Kuhnert W, et al. Seroprevalence of hepatitis A virus antibodies in the U.S.: results from the National Health and Nutrition Examination Survey. Public Health Rep 2011; 126:522-32; PMID:21800746
103. Chapman BA, Burt MJ, Frampton CM, Collett JA, Yeo KH, Wilkinson ID, et al. The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community. N Z Med J 2000; 113:394-6; PMID:11062814
104. Muscat M, Zimmerman L, Bacci S, Bang H, Glismann S, Mølbak K, et al.; EUVAC.NET group. Toward rubella elimination in Europe: an epidemiological assessment. Vaccine 2012; 30:1999-2007; PMID:22178098; http://dx.doi.org/10. 1016/j.vaccine.2011.12.016
105. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100; PMID:21566560
106. The Institute of Environmental Science and Research Ltd. Notifiable and other diseases in New Zealand: Annual Report 2011. Porirua, New Zealand, 2012.